Cutera
Defining a New Benchmark in Medical Aesthetics

Ever the last decade, there has been a paradigm shift in the medical aesthetics industry. An increasing number of customers looking for aesthetic treatments have started to prefer minimally invasive and non-invasive procedures over traditional surgical methods. The movement is rather justified as these alternatives are more economical and come with lesser pain, reduced scarring, and quicker recovery. As the demand for such treatments soars, there is a growing need among physicians to deliver faster and cost-effective patient outcomes using newer approaches to non-invasive procedures.

Addressing this need is Cutera (NASDAQ: CUTR), a publicly-traded global aesthetics company that designs, manufactures, markets, and sells a complete aesthetics product portfolio. They develop easy-to-use, safe, and effective products based on robust clinical evaluations and engineering to help physicians offer reproducible patient outcomes. “We are hyper-focused on innovating with rigor. We work closely with physicians to better understand the market, its trends, and where the demand is to develop products that drive value for them and patients,” states Jason Richey, the President of Cutera.

Cutera focuses on two major verticals within the medical aesthetics space—the face and skin and the body sculpting segments. The company’s flagship product, xeo, was one of its original technologies and still proves to be a true workhorse in many modern aesthetic practices. This multi-application platform features facial revitalization, vascular and pigmentation, hair removal and the signature Laser Genesis™ procedure. Physicians can select from multiple energy and light-based technologies, Nd:YAG Laser (1064 nm), Er:YSGG Laser, Intense Pulse Light and Infrared, to customize treatment offerings.

The company innovated the body sculpting sector with truSculptiD, which provides a personalized, hands-free device for fat reduction. It is a powerful, handsfree, non- invasive, monopolar RF tool that easily tailors to patients’ specific needs and features real-time temperature control for clinically proven results. It further treats the entire fat layer resulting in an average of 24 percent of fat reduction. This device comes with unique handpieces for placement location versatility and customized 15-minute protocol to treat multiple areas—abdomen and flanks—simultaneously.

The company also delivers the truSculpt flex, which complements the truSculptiD and is a muscle-sculpting device for personalized treatments based on the patients’ fitness level, shape, and goals. Its multidirectional stimulation (MDS) deploys a unique electrical stimulation method to target specific muscle groups using three different modes titled prep, tone and sculpt, to offer highly efficacious results to patients.

Cutera is also pioneering the vascular laser treatment market with its groundbreaking excelV+, which is used for treating all kinds of vascular anomalies and pigmented lesions. It is designed leveraging the expertise of leading dermatologists and delivers power, precision, and performance in treating vascular and pigmentary conditions.

It has two clinically proven wavelengths, large spot sizes up to 16mm, and higher energy that allows the treatment of large skin areas and pinpointed areas.

We are hyper-focused on innovating with rigor. We work closely with physicians to better understand the market, its trends, and where the demand is to develop products that drive value for them and patients

Cutera has pioneered effective hair removal with excel HR. This product combines a high-power 755nm Alexandrite laser and Cutera’s proven long-pulse 1064nm Nd:YAG laser for safe and effective high-volume hair removal on all skin types. It utilizes CoolView’s integrated sapphire contact cooling that prevents patients from getting infected by any airborne infections, especially during the current pandemic situation.

The company further delivers the enlighten portfolio of products directed toward tattoo removal and benign pigmented lesion treatments. It features both nanosecond and picosecond pulse durations to offer efficient removal of ink and pigment density. These products come with a strong, non-thermal, photomechanical effect with high-peak-power and ultra-short pulse durations that remove the targeted pigment without damaging the skin. The micro-lens array (MLA) offered with the enlighten platform is designed to treat acne scars when using the 1064 nm mode.

Apart from this, Cutera also offers two different RF devices, the Secret RF and the Fraxis PRO. The Secret RF is a fractional radiofrequency microneedling tool for tissue coagulation and hemostasis to stimulate and remodel the collagen and address the common signs of aging. It offers improvement of skin quality. Along with the Secret RF, The Fraxis PRO device combines fractional CO2 for skin resurfacing and RF microneedling for deep dermal remodeling to ultimately treat the skin’s entire thickness from the epidermis to the deeper dermal layers.

Furthermore, Cutera provides clinical training to physicians and their staff to ensure they are comfortable with them and maximize its use to deliver optimized patient outcomes. It also offers virtual workshops, in-person workshops, training symposia, and a 24-hour support line to address all questions and issues posed by physicians and their staff at all times.

With a robust en-suite of products, a strong R&D team, and innovation, Cutera is bringing world-class products for the face and skin and the body sculpting segments and venture into other uncharted waters of the aesthetic industry. The company is gradually advancing the current science and technology of its existing product portfolio with R&D to build more robust feature sets and conduct advanced clinical research to expand indications. Apart from expanding its scope of applications and treatments, Cutera is also looking to expand globally into markets in China, Korea, parts of the Middle East, and Southeast Asia.

“We will constantly work toward creating clinical reproducibility and robust data sets to help drive value for physicians, patients, and the overall practice. We ensure to deliver the best when it comes to safe and highly-effective treatments through our products,” concludes Richey.